BioMarin Q2 revenue beats estimates; raises 2026 outlook
BMRN•Growth drivers
BioMarin said a primary driver of revenue growth was the addition of GALAFOLD and POMBILITI + OPFOLDA, acquired from Amicus.
Strong global demand for VOXZOGO, with treated children increasing over 20% year over year, also contributed to revenue growth. Continued strength from PALYNZIQ and growth in the metabolic conditions portfolio supported results.
Key details and analyst coverage
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $990 million | $926.91 million (21 analysts) |
| Q2 Adjusted EPS | Beat | $1.20 | $0.69 (15 analysts) |
| Q2 EPS | $0.23 | ||
| Q2 Net Income | $45 million |
The current average analyst rating on the shares is buy, with 21 strong buy or buy ratings, 6 hold ratings and no sell or strong sell ratings.
The median 12-month price target for BioMarin Pharmaceutical Inc. is $87.83, about 46.6% above its August 5 closing price of . The stock recently traded at the next 12-month earnings, versus a P/E of three months ago.
